Introduction
In recent years, despite the availability and utilization of effective antibacterial drugs and vaccines against pneumonia, its overall mortality rate has not decreased and has even shown an upward trend (Patterson and Loebinger 2012). This underscores the urgent need for novel preventive strategies. Clostridium butyricum is a butyrate-producing, gram-positive, strictly anaerobic bacterium commonly found in the healthy intestinal tract of humans and animals (Vital et al.
2013). In Africa, C. butyricum is widely used for the management of non-antimicrobial and antimicrobial- associated diarrhea (Cassir et al. 2016).
Beyond its gastrointestinal applications, C. butyricum exhibits antibacterial activity against pathogens such as Helicobacter pylori, enterotoxigenic Escherichia coli, Vibrio Species, and Clostridium difficile (Kuroiwa et al. 1990; Takahashi et al. 2000, 2004).
Its mechanism of action involves multiple facets: C. butyricum can form metabolically dormant endospores that withstand low-pH environments and antibiotic stress (Courvalin 2006). Additionally, it produces substantial amounts of short-chain fatty acids, predominantly butyrate, which promote the differentiation of regulatory T cells (Kashiwagi et al. 2015) and downregulate the expression of virulence genes in pathogenic bacteria (Gantois et al.
2006).
In the quest for probiotics of effectively preventing pneumonia, the route of administration emerges as a pivotal factor influencing their efficacy. While oral probiotics have shown promise in reducing the incidence and severity of acute and chronic respiratory infections (Doron et al. 2005; Mortaz et al.
2013), direct delivery to the respiratory tract may offer superior local immunomodulatory and antimicrobial effects (Hori et al. 2001; Pellaton et al. 2012).
For example, intranasal administration of probiotics improved survival rate in influenza-infected mice compares to oral delivery (Youn et al. 2012), and enhanced protection against pneumococcal pneumonia (Villena et al. 2009; Zelaya et al.
2013). These findings support the concept that localized probiotic exposure can engage pulmonary immune cells and modulate the respiratory microenvironment more efficiently.
However, a key question for respiratory applications is whether a strict anaerobe can exert activity in the oxygen-rich lung. Emerging microbiological evidence indicates that certain strains of C. butyricum possess genetic adaptations that confer a degree of oxygen tolerance during vegetative growth (Camerini et al. 2019).
More importantly, in patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, or chronic bronchitis, impaired mucociliary clearance leads to mucus accumulation and biofilm formation, which together create steep oxygen gradients and hypoxic niches within the airway surface layer (Hill et al. 2022; Page et al. 2021).
This pathophysiological microenvironment may facilitate the retention and local activity of inhaled spores or bacterial components.
Building on these insights, the present study aimed to evaluate the preventive efficacy of inhaled C. butyricum delivered via oxygen-driven nebulization against drug-resistant bacterial pneumonia, comparing this approach with conventional oral probiotic administration.
Materials and methods
Patients
From November 2014 to February 2015, 310 patients with clearly diagnosed conditions including COPD, bronchial asthma, asthmatic bronchitis, chronic bronchitis, and multiple infections with drug-resistant bacteria were recruited from the First Affiliated Hospital of Shanxi Medical University and Yuncheng Central Hospital. The temperatures during this period ranged from −8 °C to 12 °C.
Inclusion criteria: aged 6 to 85 years; history of chronic respiratory disease; history of multiple infections with drug-resistant bacteria; no use of any antibiotics or other medications that could affect the observation of the efficacy of the study drug within the past 2 weeks; compliance with ethical requirements, and signed informed consent by the patient and/or family members. Exclusion criteria: Patients with consciousness disorders.
Withdrawal criteria: patients who experienced allergic reactions or serious adverse events during the treatment, patients whose disease deteriorated, patients unwilling to continue the clinical trial, patients who did not follow the prescribed regimen during the study period, patients who did not complete the course of treatment or had incomplete data, and patients who took drugs outside the study protocol that affected the efficacy observation outside the study protocol.
Study design
This study was a multicenter, randomized, single-blind, parallel control design. A total of 310 patients were enrolled and allocates to either the experimental group (n = 155) or the control group (n = 155) using a stratified block randomization procedure. Stratification was performed based on age, grouped by 10-year intervals.
Within each stratum, a computer-generated randomization sequence with a fixed block size was prepared by an independent statistician. Allocation concealment was ensured using sequentially numbered, opaque, sealed envelopes, which were opened only after a patient was formally enrolled in the study.
To minimize potential bias, the study employed a single-blind (participant-blind) design. All inhalation solutions were prepared immediately before administration by an unblinded study coordinator in a separate room not accessible to patients or the administering nurses. The active preparation consisted of a lyophilized powder of C. butyricum (containing not less than 6.3 × 106 colony-forming units [CFU]) fully dissolved in 5–8 mL of sterile water for injection.
The control inhalation solution was an identical volume of sterile water alone. Both solutions were transferred into identical, opaque nebulizer chambers to prevent visual distinction. Furthermore, all patients were instructed to rinse their mouths thoroughly with water prior to each inhalation session to mitigate any potential taste differences.
All interventions were administered once daily for 13 days, beginning three days before a forecasted temperature drop. Patients in the experimental group received inhalation of C. butyricum suspension via oxygen-driven nebulization at flow rate of 4 L/min, with each session lasting approximately 20 min. This was paired with a daily oral placebo capsule containing glucose powder.
Patients in the control group underwent an identical inhalation procedure using sterile water and received a daily oral capsule containing the same dose of C. butyricum powder (≥ 6.3 × 106 CFU). All pharmaceutical preparations were supplied by Qingdao Donghai Pharmaceutical Co., Ltd, China.
Outcome measures
Both groups were protected from respiratory infections for 13 days. The primary outcome was the incidence of pneumonia, defined in a patient with 2 or more signs (temperature > 38 °C, white blood cell counts > 10 × 109/L) or symptoms (cough, sputum production, shortness of breath, abnormal breath sounds on auscultation) of pneumonia in conjunction with consistent radiographic findings (patchy invasive opacities on chest radiography) without an alternative explanation.
Secondary outcomes were included microbiological analysis from sputum cultures obtained during follow-up. Sputum samples were collected at baseline and on days 10 post-intervention. Standard microbiological culture techniques were employed to qualitatively detect the presence of specific drug-resistant pathogens: Pseudomonas aeruginosa, extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli, methicillin-resistant Staphylococcus aureus (MRSA), and Klebsiella pneumoniae.
Clinical parameters
The demographic characteristics and medical history of the participants were collected, including age, gender, body mass index, smoking history, and vital signs such as systolic blood pressure, diastolic blood pressure, heart rate (HR), respiratory rate (RR), and body temperature. Blood tests included measurements of white blood cells, hemoglobin, platelets, prothrombin time (PT) and high-sensitivity C-reactive protein (hs-CRP).
Statistical analysis
The analysis was conducted using SPSS. The normal distribution of variables was assessed using the Shapiro–Wilk test. Data are reported as mean ± standard deviation (SD).
Differences between the two groups were analyzed using the student’s t-test or the Mann–Whitney U test, depending on the normality of the distribution. Ratios and proportions between groups were compared using the chi-square test. P-value < 0.05 was considered significant.
Results
Patient demographic and baseline characteristics
A total of 310 patients aged 6 to 85 years were enrolled and randomized. The control group comprised 155 patients (77 males and 78 females) with a mean age of 46.57 years. In the experimental group, three patients (1 male and 2 females) experienced cough and shortness of breath during the initial nebulization and were subsequently withdrawn from the study after confirmation of a pre-existing dust allergies.
Thus, 152 patients (75 males and 77 females) with a mean age of 46.15 years completed the trial in the experimental group (Table 1). Table 1Demographics and baseline clinical characteristicsCharacteristicsControl group(n = 155)Experiment group(n = 152)t/χ2P valueAge, years46.57 ± 14.6346.15 ± 17.410.2770.821GenderMale77 (49.68%)75 (49.34%)0.00350.953Female78 (50.32%)77 (50.66%)BMI, kg/m223.08 ± 3.0723.16 ± 3.45−0.2110.833Smoking history42 (27.10%)37 (24.34%)0.30470.581Prior pneumonia history102 (65.81%)96 (63.16%)0.23510.628Systolic BP, mmHg121.46 ± 19.22123.76 ± 17.24−1.1060.270Diastolic BP, mmHg76.32 ± 11.8774.01 ± 13.251.6050.110HR, beat per min81.81 ± 11.4979.59 ± 10.531.7650.079RR, breath per min18.90 ± 2.3518.49 ± 2.741.3850.167Body temperature, ℃36.69 ± 0.5036.61 ± 0.471.4780.140WBC, 109/l6.41 ± 1.996.63 ± 2.13−9.9400.348Hemoglobin, g/l114.38 ± 20.58115.61 ± 23.04−0.4910.624Platelet, 109/l242.80 ± 56.37235.65 ± 52.991.1440.253PT, s11.54 ± 1.8411.48 ± 1.910.2800.779hs-CRP, mg/l6.89 ± 3.146.63 ± 3.770.6490.517Chronic obstructive pulmonary disease58 (37.42%)63 (41.45%)0.52140.470Bronchial asthma15 (9.68%)18 (11.84%)0.37480.540Asthmatic bronchitis8 (5.16%)6 (3.95%)0.25980.610Chronic bronchitis58 (37.42%)53 (34.87%)0.21630.642Multiple drug-resistant bacteria infection138 (89.03%)126 (82.89%)2.40010.121
Baseline demographic and clinical characteristics were well-balanced between the two groups. No statistically significant differences (P > 0.05) were observed in age, gender, body mass index (BMI), smoking history, prior pneumonia history, systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), respiratory rate (RR), body temperature, white blood cell count (WBC), hemoglobin level, platelet count, prothrombin time (PT) and high-sensitivity C-reactive protein (hs-CRP). The distribution of underlying chronic respiratory conditions, including chronic obstructive pulmonary disease, bronchial asthma, asthmatic bronchitis, chronic bronchitis and history of recurrent drug-resistant bacteria, was also comparable between groups (Table 1, P > 0.05).
Clinical outcomes following prophylaxis
After 5 and 10 days of prophylactic treatment administered through different routes, significant differences in clinical characteristics emerged between the two groups. Specifically, patients in the experimental group exhibited lower body temperatures, as well as reduced levels of WBC and hs-CRP, in comparison to the control group (Table 2, P < 0.05). Imaging and clinical assessments at day 10 further reflected this divergence.
The experimental group demonstrated a markedly lower incidence of new patchy or localized infiltrates on chest X-ray and a significant reduction in purulent tracheal secretions compared to the control group (Table 3, P < 0.05). Table 2Post-intervention 5 days and 10 days comparison of the clinical characteristics in control group and experiment groupTimeCharacteristicsControl group(n = 155)Experiment group(n = 152)tP valueDay 5Body temperature, ℃37.24 ± 0.9436.68 ± 0.426.608 < 0.001WBC, 109/l8.17 ± 3.336.84 ± 2.773.818 < 0.001hs-CRP, mg/l18.34 ± 25.358.71 ± 8.264.456 < 0.001Day 10Body temperature, ℃37.62 ± 0.9936.65 ± 0.4011.254 < 0.001WBC, 109/l10.23 ± 3.058.39 ± 2.226.046 < 0.001hs-CRP, mg/l27.18 ± 29.6114.30 ± 20.434.430 < 0.001Table 3Post-intervention 10 days comparison of the chest X-ray and tracheal tube secretions in control group and experiment groupCharacteristicsControl group(n = 155)Experiment group(n = 152)χ2P valueChest X-rayWith no change68 (43.87%)119 (78.29%)38.183 < 0.001Patchy infiltration47 (30.32%)30 (19.74%)4.5770.032Local infiltration40 (25.81%)3 (1.97%)36.190 < 0.001Tracheal tube secretionNo secretion9 (5.81%)22 (14.47%)6.3500.012None infective secretions74 (47.74%)127 (83.56%)43.535 < 0.001Purulent secretions72 (46.45%)3 (1.97%)82.234 < 0.001
The pneumonia incidence of two groups
The cumulative incidence of pneumonia within the 10-day observation period following a cold-spell trigger was the primary outcome. In the control group, 45 patients were diagnosed by day 5, with an additional 27 patients by day 10, yielding a total incidence of 46.45% (72/155). Conversely, in the experimental group, recorded only 2 cases by day 5 and 1 additional case by day 10, resulting in an incidence of 1.97% (3/152).
The risk of developing pneumonia was 23.54 times higher in the control group compared to the experimental group (Table 4, Fig. 1, RR = 23.54, 95%CI: 7.58–73.08, P < 0.01). Table 4Post-intervention 5 days and 10 days comparison of incidence of pneumonia in control group and experiment groupEventsControl group(n = 155)Experiment group(n = 152)RRCI (95%)P valuePneumonia (Day 5)Yes45 (29.03%)2 (1.32%)22.075.45–89.35 < 0.001No110 (70.97%)150 (98.68%)Pneumonia (Day 10)Yes72 (46.45%)3 (1.97%)23.547.58–73.08 < 0.001No83 (53.55%)149 (98.03%)RR, relative risk; CI, confidence intervalFig.
1An experimental evaluation of the effect of different route of administration on preventing pneumonia. Control group, broken line; Experiment group, solid line
Microbiological outcomes
Sputum cultures were analyzed for specific drug-resistant pathogens commonly associated with pneumonia (Henig and Kaye 2017), including Pseudomonas aeruginosa, ESBL-producing Escherichia coli, MRSA and Klebsiella pneumoniae. Compared to the control group, patients received inhaled of C. butyricum showed a statistically significant reduction in the rate of sputum cultures positive for Pseudomonas aeruginosa, ESBL-producing Escherichia coli and Klebsiella pneumoniae (Table 5, P < 0.05). The proportion of cultures positive for MRSA was also lower in the experimental group, although this difference did not reach statistical significance (P > 0.05).
Table 5Post-intervention 10 days comparison of distribution of microorganisms detected in sputum in in control group and experiment groupPathogenic bacteriaControl group(n = 155)Experiment group(n = 152)χ2P valuePseudomonas aeruginosa20 (12.90%)3 (1.97%)13.227 < 0.001ESBL-producing Escherichia coli30 (19.35%)10 (6.58%)11.0540.001MRSA4 (2.58%)3 (1.97%)0.1270.722Klebsiella Pneumoniae33 (21.29%)12 (7.89%)11.0080.001
Discussion
This prospective, multicenter, randomized controlled trial provides compelling evidence supporting the efficacy of inhaled C. butyricum delivered via oxygen-driven nebulization for the prevention of drug-resistant bacterial pneumonia. The results demonstrate a profound reduction in pneumonia incidence, alongside improvements in systemic inflammatory markers and respiratory microbiology, favoring the inhaled route over standard oral probiotic administration. This study introduces a novel, targeted approach to harnessing the immunomodulatory potential of C. butyricum for respiratory protection, particularly in high-risk populations with chronic lung disease.
The primary outcome, a 23.54 lower risk of pneumonia in the experimental group, is striking. This aligns with the foundational concept that direct delivery can optimize local bioavailability. While oral C. butyricum is known to modulate systemic immunity via the gut-lung axis (Doden et al.
2021), its inhaled administration allows for direct interaction with the respiratory mucosal immune system. Crucially, the biological plausibility of delivering an anaerobic bacterium to the airway is supported by emerging microbiological insights. First, specific strains of C. butyricum exhibit genetic traits conferring notable aerotolerance (Camerini et al.
2019). Second, the pathophysiology of our target population (COPD, chronic bronchitis) is characterized by impaired mucociliary clearance. The resultant thickened mucus layer and potential biofilm formation create steep oxygen gradients and hypoxic niches within the airways (Hill et al.
2022; Page et al. 2021), providing a plausible microenvironment for the transient retention or activity of delivered bacterial components, even if oxygen-sensitive.
Our results may be consistent with a "postbiotic" mode of action, wherein the therapeutic effect is mediated by bacterial structural components or pre-formed metabolites rather than colonization by live anaerobes. This is supported by studies showing that heat-inactivated C. butyricum or its cell-free supernatant retains significant immunomodulatory capacity in respiratory models (Li et al. 2022; Liu et al.
2024). The inhaled preparation, primarily composed of resilient spores, may act through several interconnected pathways: 1) Immunomodulation: Spore and cell wall components (e.g., peptidoglycan) can engage pattern-recognition receptors on alveolar macrophages and airway epithelial cells, potentially skewing responses toward an anti-inflammatory phenotype (Mann et al. 2024; Mortaz et al.
2013). 2) Metabolite activity: Butyrate and other short-chain fatty acids, either present in the formulation or potentially produced by spores in hypoxic micro-niches, are potent mediators known to enhance epithelial barrier function, reduce pro-inflammatory cytokine production, and promote regulatory T-cell responses (Kashiwagi et al. 2015).
3) Microecological competition: Even transient presence in the airways may interfere with pathogen adhesion or nutrient availability (Buffie and Pamer 2013; Terada et al. 2020).
The reduction in body temperature, WBC count and hs-CRP levels in the experiment group underscore a potent systemic anti-inflammatory effect, likely stemming from localized action in the lung. Corresponding improvements in chest X-ray findings and tracheal secretions further indicate a positive impact on respiratory pathophysiology. The notable reduction in sputum culture positivity for key drug-resistant Gram-negative pathogens (Pseudomonas aeruginosa, ESBL-producing Escherichia coli, Klebsiella pneumoniae) is particularly encouraging, suggesting a direct or indirect suppressive effect on colonization.
These pathogens are commonly associated with acquired pneumonia and are often resistant to conventional antibiotics (Chastre and Fagon 2002). It is important to note that this analysis was qualitative (presence/absence); future studies employing quantitative cultures (CFU/mL) would provide deeper insight into the magnitude of pathogen suppression.
Several methodological aspects warrant specific discussion. The high pneumonia incidence (46.45%) in the control group (oral C. butyricum) is notable and likely reflects the intrinsically high risk of the enrolled cohort that patients with chronic respiratory diseases and a history of resistant infections, and studied during a provoking cold spell. This high baseline rate accentuates the clinical relevance of the observed protective effect.
Regarding the safety and feasibility of the oxygen-driven delivery method, the use of medical-grade oxygen (4 L/min) does create a transient hyperoxic stream during nebulization. However, concerns regarding oxygen toxicity to the bioactive components are mitigated by several key factors: the formulation consists predominantly of metabolically dormant spores, renowned for their extreme resilience to oxidative and environmental stress; the exposure duration during the brief aerosolization process is limited; and the target patient population inherently possesses hypoxic airway microenvironments due to mucus pathology, which may aid in preserving component activity. Most importantly, the clinical efficacy observed in this trial, coupled with the absence of serious adverse events related to the inhalation procedure, provides preliminary evidence for the safety and tolerability of this method.
Preclinical studies using inhaled heat-inactivated C. butyricum have also reported no significant safety issues (Li et al. 2022; Liu et al. 2024).
While we did not perform in-line viability assays or characterize the aerosol's particle size distribution in this efficacy trial, these are important pharmacokinetic parameters for future translational work to standardize dosing.
This study has several limitations should be acknowledged. First, the single-blind design, while employing rigorous procedural controls (opaque nebulizers, pre-procedure mouth rinsing), could not fully mask the intervention from all participants due to the physical nature of the bacterial suspension. However, objective, blinded assessment of the primary endpoint mitigates this concern.
Second, the mechanistic insights are inferred. We did not directly measure local butyrate concentrations in the airways, quantify the viable fraction of spore’s post-nebulization, or perform detailed immune profiling. The microbiological outcomes, while clinically relevant, were qualitative.
Third, the long-term safety and durability of protection beyond the 13-day intervention period remain unknown. Future studies should prioritize: 1) Mechanistic elucidation: Employing techniques like bronchoalveolar lavage in animal models or carefully designed sub-studies to measure local pharmacodynamics (e.g., metabolite levels, immune cell activation). 2) Aerosol characterization: Defining the emitted dose, fine particle fraction, and particle size distribution of the C. butyricum aerosol to optimize delivery.
3) Extended follow-up: Assessing long-term efficacy and safety. 4) Broader applications: Exploring this delivery platform for other respiratory conditions where immune modulation and microbiome management are therapeutic goals. In conclusion, this study demonstrates that inhaled C. butyricum via oxygen-driven nebulization is an effective intervention for the prevention of pneumonia with drug-resistant bacteria in a vulnerable population.
It underscores the therapeutic potential of targeted, local probiotic/postbiotic delivery, moving beyond traditional oral paradigms. These findings warrant both confirmation in larger trials and dedicated research to unravel the precise mechanisms of action, paving the way for a novel preventive tool in the ongoing challenge of antimicrobial resistance.